Iridex Reports Preliminary Q4 2025 Revenue Of $14.6M–$14.8M, Up 15%–17% YoY, And Full-Year Revenue Of $52.5M–$52.7M, Up 8% YoY, While Achieving Positive Cash Flow And Adjusted EBITDA

Fourth Quarter 2025 Results

• Total revenue is expected to be between $14.6 million and $14.8 million compared to $12.7 million in the prior year quarter, representing year-over-year growth between 15% and 17%
• Achieved positive cash flow in the fourth quarter
• Sold 15,800 Cyclo G6® probes compared to 13,300 in the prior year quarter
• Sold 44 Cyclo G6 Glaucoma Laser Systems, compared to 47 in the prior year quarter

Full Year 2025 Results

• Total revenue is expected to be between $52.5 million and $52.7 million compared to $48.7 million in 2024, representing year-over-year growth of 8%
• The company expects to achieve positive adjusted EBITDA in 2025
• Sold 57,700 Cyclo G6® probes, compared to 55,400 in the prior year
• Sold 133 Cyclo G6® Glaucoma Laser Systems compared to 125 in the prior year